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In Brief
HIV latency allows the virus to evade
eradication under modern treatment
regimens. Now, it appears that there is an
evolutionary advantage to latency as well.
Latency may have remained hardwired
into the HIV genome to enhance lentiviral
transmission across the target-cell-poor
mucosa.
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HIV latency is the chief obstacle to eradicatingHIVbut
is widely believed to be an evolutionary accident
providing no lentiviral fitness advantage. However,
findings of latency being ‘‘hardwired’’ into HIV’s
gene-regulatory circuitry appear inconsistent with la-
tency being an evolutionary accident, given HIV’s
rapid mutation rate. Here, we propose that latency is
an evolutionary ‘‘bet-hedging’’ strategy whose fre-
quency has been optimized to maximize lentiviral
transmission by reducing viral extinction during
mucosal infections. The model quantitatively fits the
available patient data, matches observations of
high-frequency latency establishment in cell culture
and primates, and generates two counterintuitive
but testable predictions. The first prediction is that
conventional CD8-depletion experiments in SIV-in-
fected macaques increase latent cells more than
viremia. The second prediction is that strains engi-
neered to have higher replicative fitness—via reduced
latency—will exhibit lower infectivity in animal-model
mucosal inoculations. Therapeutically, the theorypre-
dicts treatment approaches that may substantially
enhance ‘‘activate-and-kill’’ HIV-cure strategies.INTRODUCTION
HIV actively replicates in CD4+ T lymphocytes but can also enter
a long-lived quiescent state termed proviral latency in memory
CD4+ T cells (Chun et al., 1997a; Finzi et al., 1997). The popula-
tion of latently infected cells is relatively small in patients (1 in
106 CD4+ T cells) and does not generate significant viral RNA
(Pierson et al., 2000). However, latently infected cells provide a
critical viral reservoir, which enables lentiviral persistence even
during prolonged antiretroviral therapy (ART). Further, if patients
interrupt ART, persisting latent viruses reactivate, driving HIV to
pre-treatment viral loads within weeks (Richman et al., 2009).
Consequently, latency is the chief barrier to a curative HIV
therapy.1002 Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc.While latency enables HIV to avoid extinction during ART, the
benefitof latencyprior to theARTera—during thecenturies of nat-
ural lentiviral infections—remains unclear. In fact, latency appears
to have been deleterious prior to ART since latently infected cells
produce no virus and decrease patient viral loads. Given latency’s
reduction of lentiviral replicative fitness, the prevailing hypothesis
is that latency is an evolutionary accident—an epiphenomenon
that only resultswhen lentiviruses infectCD4+ T cells that are tran-
sitioning from activated to quiescent memory states (Coffin and
Swanstrom, 2013;Eisele andSiliciano, 2012;Hanet al., 2007). La-
tency is therefore viewed to be an infrequent bystander effect that
onlyoccursafter aviral-drivenadaptive immune response initiates
and CD4+ T lymphocytes begin to form memory subsets. Yet, a
recent study in Rhesus macaques indicates that latency reaches
high levels within the first 3 days of infection (Whitney et al.,
2014), which is prior to the generation of an SIV-specific adaptive
immune response (Kuroda et al., 1999).
If latency were a non-beneficial viral trait or epiphenomenon,
one would expect it to have been lost due to natural selection
or genetic drift, given lentiviruses’ rapid evolutionary rates. Yet,
a companion study (Razooky et al., 2015 [this issue of Cell])
demonstrates that the ability to establish latency is ‘‘hardwired’’
into HIV’s gene-regulatory circuitry. This study matches recent
data showing that 50% of cell-culture infections—in which
adaptive immune responses are absent—result in lentiviral la-
tency (Calvanese et al., 2013; Dahabieh et al., 2013). Further,
HIV’s auto-regulatory Tat circuit appears optimized to amplify
stochastic fluctuations in viral gene expression, producing fluc-
tuations that are sufficient to induce a probabilistic switch to la-
tency (Burnett et al., 2009; Weinberger et al., 2005; Weinberger
et al., 2008). In general, stochastic expression noise is thought
to be selected against and thus filtered out of regulatory circuits
when not beneficial (Batada and Hurst, 2007; Fraser et al.,
2004). The persistence of a hardwired latency circuit suggests
an unknown selective advantage, which outweighs latency’s
putative fitness cost of reducing long-term viral loads.
One possible selective benefit is that—by providing a long-
lived viral reservoir—latency could enhance lentiviral survival
during unfavorable environmental conditions. Similar ‘‘bet-hedg-
ing’’ hypotheses (Cohen, 1966) have been proposed for bacte-
riophage-l lysogeny (Arkin et al., 1998) and bacterial persistence
(Balaban, 2011). However, lentiviral latency would only provide a
bet-hedging advantage if there were risks of viral extinction due
to environmental fluctuations. In reality, lentiviruses appear in lit-
tle danger of population crashes, as they evade immune clear-
ance and maintain high viral loads of 105 particles/ml of blood
plasma for years (and lentiviruses clearly did not evolve under
pressure from antiretroviral drugs). Further, lentiviruses only
infect a small percentage (1%–2%) of available target cells,
making target-cell fluctuations unimportant during chronic infec-
tion. Nevertheless, viral loads remain low during one phase of the
lentiviral lifecycle: initial mucosal infection.
The probability of successful mucosal infection is low, with
<1% of unprotected sex acts between HIV-discordant couples
resulting in self-propagating systemic HIV infections (Fraser
et al., 2007; Gray et al., 2001; Wawer et al., 2005). When suc-
cessful infections do occur, they expand from single founder se-
quences (Kearney et al., 2009; Keele et al., 2008), indicating that
only one variant in the transmitted quasispecies avoids extinc-
tion. Further, animal models of HIV capture a consistent
6 day delay from experimental mucosal inoculation to self-
propagating infection (Haase, 2011; Zhang et al., 1999), which
implies that the first days of lentiviral infection provide conditions
unsuitable for viral growth.
Theunfavorable conditions of early lentiviral infections typically
occur in the mucosa, where >90% of HIV infections initiate
(Haase, 2011). HIV’s evolutionary precursor in non-human pri-
mates (SIV) also spreads through mucosal transmission—via
sexual activity or fighting with subsequent communal wound
licking (Santiago et al., 2005). Mucosal challenge experiments
in primates with large inoculations provide direct evidence that
the mucosa are initially unfavorable to lentiviral growth: large
inoculations of 109 infectious units (by TCID50) initially burn
outwithin5days (Miller et al., 2005).Quantitatively, each initially
infected cell lives for1 day (Markowitz et al., 2003), so the num-
ber of actively infected cells after 5 days scales with (R0
muc)5—
wherein R0
muc is the basic reproductive ratio during early
mucosal infection. Since actively infected cells crash within
5 days (Miller et al., 2005), (R0muc)5 approaches 0, implying
that R0
muc < < 1 during initial mucosal infection.
Here, we quantitatively test the hypothesis that latency pro-
vides a bet-hedging advantage that increases the probability of
successful lentiviral transmission despite reducing viral loads
during systemic infection (Figure 1A). The key point is that
increasing the probability of latency (plat) increases the probabil-
ity that each initially infected cell survives initial mucosal infec-
tion. Yet, increasing plat also decreases viral loads in systemi-
cally infected hosts, which reduces the inoculum transmitted to
new hosts. With a higher per-cell survival rate but fewer initially
infected cells, the question is whether latency’s fitness benefits
outweigh its costs—which would establish latency as an evolu-
tionarily beneficial trait that is maintained by natural selection.
RESULTS AND DISCUSSION
Mathematical Models of Lentiviral Transmission
and Rationale for Models
Three classes of mathematical models are developed to quantify
the net impact of latency on lentiviral transmission (Figure S1).
Each class of models generalizes the well-parameterized basic
model of viral dynamics (Nowak and May, 2000) to includeboth proviral latency and the conditions of early mucosal infec-
tion (i.e., R0
muc < 1) during which latency may be critical (Exper-
imental Procedures).
The first class of models tracks initial lentiviral infection in the
mucosa alone (Extended Experimental Procedures, Section A).
Given the small numbers of infected cells during initial mucosal
infection, the established model of mucosal infection is stochas-
tic (Pearson et al., 2011). We analyze this experimentally param-
eterized stochastic model—and a deterministic approximation
to this model—to quantify how the probability of viral extinction
in the mucosa depends on the probability of latency (plat).
The second class of models extends the single-compartment
model into a two-compartment model (Figure 1B) that tracks
both initial infection in the mucosa and systemic infection in
the lymphoid tissue (Extended Experimental Procedures, Sec-
tion B). Importantly, the initial and systemic infectionmodel com-
partments only differ in a single experimentally measured param-
eter: R0 (Figure 1B and Table S1). Collectively, the models
predict an optimal value of plat (p
opt
lat = 0.5) that matches latency
frequencies measured in cell culture (Calvanese et al., 2013; Da-
habieh et al., 2013) and is consistent with latency levels
measured in mucosal primate infections (Whitney et al., 2014).
However, the large value of plat does not match the low fre-
quencies of latency observed in chronically infected patients
(Chun et al., 1997b; Ho et al., 2013).
The third class of models incorporates a canonical immune
response (Nowak and May, 2000) into the two-compartment
model (Extended Experimental Procedures, Section C)—since
a key difference between cell-culture models and chronic infec-
tion is the presence of an adaptive immune response. Each
immune parameter added is either tied to a distinct patient-
measured value or has beenmeasured previously in the literature
(TableS2).With noadded freeparameters, the immunemodel fits
all available patient data and predicts the same robust poptlat value.
Latency’s Net Evolutionary Impact Is the Product of Its
Impact on Both Initial Infection and Systemic Infection
To calculate the optimal plat value, the two-compartment models
track latency’s net evolutionary impact across bothmucosal and
systemic infections. While the nonlinear models are complex, we
decouple latency’s net impact on viral transmission into a prod-
uct of two factors: (1) the average initial inoculum of infected cells
per mucosal inoculation (I0), and (2) the probability that an initially
infected cell establishes systemic infection (pestab) (Figure 1A).
This product can be derived analytically when the number of in-
fected cells is Poisson distributed and when each infected cell
lineage is statistically independent. Under these two assump-
tions, the probability of lentiviral transmission per-mucosal inoc-
ulation (ptransmission) reduces to:
ptransmission = 1 epestab I 0zpestab I 0 [1]
The equality in Equation [1] is a direct calculation of thePoisson
probability that at least one infected cell in the inoculum I0 estab-
lishes systemic infection. Critically,ptransmission < 10
2 since <1%
of lentiviral infections result in self-propagating infections (Gray
et al., 2001; Wawer et al., 2005). Given the equality, ptransmission <
102 immediately implies that pestab I0 < 102.Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc. 1003
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Figure 1. HIV Latency as a Bet-Hedging
Strategy for Maximizing Viral Transmission
(A) Schematic of the lentiviral transmission pro-
cess. Lentiviral transmission is illustrated as a
two-compartment process, beginning with viral
inoculation in the mucosa and progressing—in
some cases—to systemic infection in the
lymphoid tissue, where >98% of CD4+ T cells
reside (Murphy, 2011). The parameter plat reflects
the probability that an HIV-infected cell enters
latency. An HIV strain incapable of entering la-
tency (plat = 0) would generate increased viral
loads during systemic infection, transferring more
virions to new hosts. However, the latency-inca-
pable virions would rapidly destroy the small
CD4+ T cell population initially present in the
mucosa of the new host—reducing the proba-
bility of systemic infection (upper). In contrast, an
HIV strain capable of entering latency (plat > 0)
would generate lower viral loads during systemic
infection, transferring fewer virions to new hosts.
Yet, the relatively few transferred virions would
not destroy all mucosal target cells. By entering
long-lived latency in some mucosal cells, the la-
tency-capable strain would increase its proba-
bility of surviving initial infection to establish
systemic infection (lower).
(B) Schematic of the two-compartment model of
lentiviral transmission. The two major processes
controlling the probability of lentiviral trans-
mission (ptransmission) are: (1) the inoculum of in-
fected cells (I0) and (2) the probability that an
infected cell in the inoculum survives initial
infection to establish systemic infection (pestab).
(Right to left) HIV enters a host mucosal site, but
due to the small number of permissive target
cells in the early mucosa (prior to day 6), R0 < 1.
To successfully establish systemic infection, the
virus must avoid extinction until R0 > 1. Critically,
the likelihood of an actively infected cell or a free
viral particle surviving until day 6 to initiate sys-
temic infection is negligible since virus-produc-
ing cells die within 40 hr of infection and viral
progeny are cleared from the system 100-fold
more rapidly. In contrast, latently infected cells
are long-lived and can reactivate once R0 > 1 to initiate systemic viral expansion. Therefore, despite reducing long-term viral loads, latency may increase
ptransmission by increasing viral survival during initial infection. This would make latency evolutionarily beneficial at the population scale.
See also Figure S1.Having used the equality to establish that pestab I0 <102, we
can discard the quadratic and higher-order terms in the Taylor
Series expansion of epestab I 0 with negligible impact. This leads
to the subsequent approximation (i.e., linearization) in Equation
[1]: ptransmissionzpestab I 0.
Given Equation [1], the overall goal of determining whether la-
tency’s benefits outweigh its costs reduces to quantifying la-
tency’s impact on pestab and I0.
Latency Increases the Probability that an Initially
Infected Cell Survives Mucosal Infection and
Establishes Systemic Infection
To quantify latency’s impact on pestab, we begin by tracking len-
tiviral survival during mucosal infection alone. As noted above,
the first 5 days of mucosal infection are characterized by a1004 Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc.lack of detectable actively infected cells (Li et al., 2005;
Miller et al., 2005), indicating that R0 in the mucosa (R0
muc) is
initially < < 1 (Extended Experimental Procedures, Section D).
R0
muc < < 1 is also consistent with the infrequency of successful
mucosal transmissions (ptransmission < 0.01) and the6-day delay
before systemic infection when lentiviral infections do establish
(Miller et al., 2005).
Both deterministic differential equations models (Figure 2A)
and stochastic Monte-Carlo models (Figures S2A and S2B) cap-
ture the fitness advantage of latency in the mucosa. Model sim-
ulations are performed with R0 < 1 and an inoculated dose of vi-
rus that results in a few dozen initially infected cells, matching
animal mucosal experiments (Haase, 2011; Miller et al., 2005;
Zhang et al., 1999). The quantitative models show that—in the
absence of latency—all virions and infected cells are driven
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Figure 2. An Evolutionary Optimum for Latency
(A) Numerical solutions to Equation [6] showing the dynamics of latently infected cells in early mucosal infection (R0
muc = 0.25). As plat increases, the number of
surviving latently infected cells increases. (Inset) The dynamics of actively infected cells in early mucosal infection showing that as plat increases, actively infected
cells reach extinction more rapidly.
(B) In systemic infection, (R0
LT = 10), increases in plat decrease the virus load (and, therefore, the viral dose transmitted to the next host). Dynamics in (A and B) are
calculated numerically from Equation [6], using the parameters in Table S1 (r = 0).
(C) Schematic flowchart of the derivation of the (optimal) latency probability poptlat that maximizes ptransmission. Red text indicates key assumptions made at each
step of the derivation. For example, R0
muc < < 1 implies that the vast majority of latently infected cells during initial infection are produced in the first generation,
leading to the approximation LR0>1init z plat I0. The results of the analytic derivation quantify the tradeoff of latency: increasing plat linearly increases pestab but
decreases I0 by the factor (1-plat). Since this tradeoff is almost equally balanced, the optimal latency probability, p
opt
lat , approximately equals 0.5.
(D) Normalized probability of host-to-host transmission (ptransmission) as a function of plat. Results shown are obtained either analytically, from Equation [5]
(magenta line), or numerically using the plateau levels of actively infected cells (I) and latently infected cells (L) simulated in A and B (magenta dots). As in C, the
probability of transmission is maximized when plat 0.5.
(E) Normalized probability of host-to-host transmission when systemic infections emerge from non-latent routes (e.g., dendritic cells) with probability fnonlatent > 0
(Equations [S12 and S13]). The maximum probability of transmission occurs at slightly lower plat values, but p
opt
lat is still large.
See also Figure S2.extinct in the first 5 days of mucosal infection (Figures 2A, inset,
and S2A). In contrast, low levels of latency enable viral survival
(Figures 2A and S2B). To test the robustness of these predictions
across all R0 < 1 and I0 < 100, a continuous-time branching-pro-cess model was developed (Grimmett and Stirzaker, 1992). The
branching-process model (Extended Experimental Procedures,
Section A) directly computes the viral extinction probability as
a function of time, providing an efficient alternative to averagingCell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc. 1005
thousands of Monte-Carlo simulations for each R0 and I0. In the
absence of latency, the viral extinction probability approaches 1
by day 5 of mucosal infection, except in the small slice when R0
z1 (Figures S2C and S2D)—which does not match the levels of
R0 inferred from animal mucosal challenge experiments (Miller
et al., 2005).
For completeness, the surviving number of mucosally infected
cells was directly computed using a Wright-Fisher model (Hartl
and Clark, 2007; Extended Experimental Procedures, Section
A). The Wright-Fisher simulations demonstrate that the surviving
number of mucosally infected cells increases approximately lin-
early with plat for each I0 (Figures S2E–S2G). This linear depen-
dence can also be derived analytically. Given that R0
muc < < 1
during initial mucosal infection, the majority of latently infected
cells are produced in the first generation of infection (Extended
Experimental Procedures, Section A). Since these cells are un-
likely to reactivate during the short duration of initial infection,
the number of latently infected cells that survive mucosal infec-
tion iszplatI0, the latent fraction of the inoculum. Thus, both sim-
ulations and analytics indicate that increasing plat approximately
linearly increases the number of infected cells that survive initial
mucosal infection.
Given that latency appears to increase viral survival in the early
mucosa, we next tested whether latency increases the probabil-
ity of systemic infection, which mainly occurs in the lymphoid tis-
suewhere >98%of CD4+ T cells reside (Murphy, 2011). To do so,
the Wright-Fisher model was extended into a two-compartment
model that directly captures the two typical stages of lentiviral
infection: early mucosal infection and systemic (lymphoid) infec-
tion (Extended Experimental Procedures, Section B). Only a sin-
gle parameter value is assumed to differ between the early
mucosal and systemic infection compartments. While R0
muc is
parameterized to be <1, R0 during systemic infection in the
lymphoid tissue (R0
LT) is set to 10 tomatch its value in chronically
infected patients (Nowak and May, 2000).
The two-compartment model fits the available human and an-
imal data of early infections, showing that: (1) only a small frac-
tion of mucosal infections result in systemic infections (Fraser
et al., 2007), (2) successful systemic infections emerge after
5–7 days (Haase, 2011), and (3) systemic infections initiate
from single ‘‘founder’’ infected cells (Kearney et al., 2009; Keele
et al., 2008). More importantly, the two-compartment model
directly shows that latency increases the probability (pestab) of
systemic infection—with pestab maximized when plat > 0.6 (Fig-
ure S2H; Extended Experimental Procedures, Section E).
Latency Decreases the Inoculum in a New Host
While increasing plat increases the probability of systemic
lymphoid infection for any given inoculum of initially infected
cells (I0), the probability of lentiviral infection also depends on
I0 itself. Critically, I0 is proportional to the viral load of the trans-
mitting patient (Extended Experimental Procedures, Equation
S4). Thus, we can quantify latency’s impact on I0 by measuring
latency’s impact on viral loads in systemically infected
patients.
To track latency’s effect on systemic viral loads, we simulated
the deterministic model in the lymphoid compartment alone (i.e.,
R0 = 10). Initial mucosal infection was not tracked in these simu-1006 Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc.lations because of the data showing that systemic infections
emerge from single ‘‘founder’’ viruses independent of the inoc-
ulum (Kearney et al., 2009; Keele et al., 2008). These data indi-
cate that mucosal dynamics affect the probability of systemic
infection, but not the level once established. Thus, we assumed
the existence of a single founder infected cell and solved Equa-
tion [6] numerically. Assuming successful systemic establish-
ment, the systemic infectionmodel shows that increasing plat de-
creases long-term viral loads (Figure 2B). Consequently,
increasing the frequency of latency (plat) decreases infection
inocula (I0) at the population scale.
The Evolutionarily Optimal Probability of Latency Is0.5
Given Equation [1], if latency’s benefit to pestab exceeds its cost
to I0, then latency increases the probability of lentiviral transmis-
sion (ptransmission). Mathematically, this net evolutionary benefit of
latency can only occur if the (evolutionarily optimal) value of plat
that maximizes ptransmission is greater than 0. Here, we test
whether the maximizing value of plat is greater than 0, directly
quantifying latency’s net evolutionary benefit.
We first derive pestab as a function of plat. After initial mucosal
infection, only latently infected cells persist, with the number of
surviving latently infected cells defined to be LR0>1init . As noted
above, due to R0
muc < < 1, the majority of mucosal latent
infections emerge in the first generation of infection, making
LR0>1init z platI0 (Figures 2A, S2F, and S2G). At least one of these
surviving infected cells must be reactivated (with probability
preact) to establish systemic infection. Thus, the per-inoculum
probability of establishing systemic infection is:
pestab =
 
LR0>1init
I0
!
preact zplatpreact [2]
Equation [2] emerges from the result that only latently infected
cells survive initial infection in the mucosa (Figures 2A and S2A–
S2E). To demonstrate robustness, below we introduce a
‘‘leakage’’ probability (fnonlatent) that reflects the fraction of sys-
temic infections that are established by non-latent cells—
including Langerhans dendritic cells, actively infected cells,
and free virions.
We next solve for I0 as a function of plat. As noted above, the
average infectious dose (i.e., I0) that can be transmitted to a
new individual is directly proportional to the time integral of the
viral load—! V(t)dt, Equation [S4]—over the duration of systemic
infection (Nowak and May, 2000). Analytically solving this time
integral yields (Extended Experimental Procedures, Section B):
I0zconstðplatÞ
ð1 platÞRLT0  1 [3]
The constant term in Equation [3] only implies constant in
plat—it may depend on other parameters. Further, Equation [3]
is solved under the assumption that latently infected cells rarely
reactivate prior to cell death (i.e., r < < dL in Table S1). This con-
servative assumption reduces the optimal level of latency by
presuming that latently infected cells generally die before
contributing to viral loads. Given this maximal fitness cost, la-
tency reduces the reproductive ratio during systemic infection,
R0
LT, by the factor (1 plat).
By combining Equations [1–3], ptransmission emerges as a func-
tion of plat (Figure 2C):
ptransmissionzpestab I0zconstðplatÞpreactplat
ð1 platÞRLT0  1 [4]
Equation [4] shows that, for each value of R0
LT, the probability
of viral transmission has an optimum at a specific plat. To
analytically derive this optimum, we make the simplifying
assumption that preact is constant in plat. This makes
ptransmissionfplat,½ð1 platÞRLT0  1. Differentiating the simplified
transmission probability with respect to plat yields the following
optimal probability of latency, denoted poptlat :
poptlat z
1 1RLT0 
2
[5]
Strikingly, for a typical value of R0
LT 10 (Nowak and May,
2000), poptlat z0:5 is the probability of latency that maximizes len-
tiviral transmission (Figure 2C).
In agreement with these analytic derivations, numerical solu-
tions also show that ptransmission has an optimum at plat z 0.5
(Figure 2D). The numerical simulations are generated by directly
calculating ! V(t)dt in model runs, rather than approximating it via
Equation [3]. Sensitivity analyses show that this optimum at
platz0:5 exists across the entire observed range of R0
LT values
(Figure 2D).
Large Optimal Latency Probability Is Robust to Changes
in Model Assumptions
The main prediction of a large poptlat value remains valid even if
one removes key mathematical assumptions. In particular, the
two-compartment Wright-Fisher model (Extended Experimental
Procedures, Section B) inverts the assumption that preact is
constant in plat, allowing preact to strongly decrease in plat.
Even in this extreme scenario—in which latency has a substan-
tial fitness cost beyond its reduction of viral loads during sys-
temic infection—poptlat > 1/3 (Figure S2I). Similarly, the large
poptlat value remains valid when one relaxes the assumption
that only latently infected cells seed systemic infections. To
show this, we analytically re-calculated poptlat when a fraction
(fnonlatent) of successful infections are established via non-latent
routes (Extended Experimental Procedures, Section E). Even if
80% of lentiviral transmissions are established via non-latent
routes, poptlat = 0.1. More generally, as long as fnonlatent is less
than 100%, latency remains evolutionarily beneficial (Figures
2E and S2J).
Strikingly, relaxing other model assumptions increases the
large poptlat value. For example, relaxing the assumption that
latently infected cells die prior to reactivation (i.e., r < <
dL) reduces the cost of latency during systemic infection
and therefore increases the optimal latency probability. In
fact, if r R dL, p
opt
lat = 1 (Extended Experimental Procedures,
Section E). Further, if lentiviral transmissibility saturates at
high viral loads (Fraser et al., 2007)—so that latency’s
decrease of steady-state viral loads does not decrease
I0—then p
opt
lat would again equal 1, due to the absence
of a cost to latency (Extended Experimental Procedures,
Section E).Simplified Two-Compartment Model Fits the High
Frequencies of Latency Measured in Experimental
Models
The predicted value of poptlat 0.5 matches the latency fre-
quencies of 50% (Dahabieh et al., 2013) or higher (Calvanese
et al., 2013) measured in cell culture. poptlat 0.5 is also consis-
tent with a recent in vivo study in Rhesus macaques, in which a
large reservoir of latently infected cells is documented on day 3
of mucosal infection (Whitney et al., 2014). However, poptlat 0.5
is inconsistent with the low latency frequencies measured in
chronically infected patients. Only 1 in 106–107 patient CD4+
T cells appear to be latently infected (Chun et al., 1997a; Seda-
ghat et al., 2007). This has led to estimates of plat 105 104
(Rong and Perelson, 2009a; Sedaghat et al., 2007). While more
recent studies indicate that the latency frequency in patient
cells is 60-fold higher (Ho et al., 2013), this still leaves plat <
< 0.5 during chronic infection. Below, we show that the dichot-
omy between latency’s high frequency in early infection and
cell culture and latency’s low frequency in chronic infection
can be explained by the onset of the adaptive immune
response.
Mathematical Models Incorporating the Immune
Response Are Required to Explain the Divergent
Latency Frequencies between Experimental Models
and Patients
Unlike early mucosal infections or cell-culture infections, chronic
lentiviral infections contain an HIV-specific adaptive immune
response (Turnbull et al., 2009). Previous work has shown that
this adaptive immune response must be incorporated into the
basic model of viral dynamics (De Boer and Perelson, 1998;
Nowak and May, 2000) to fit the 2–3 log drop in viral loads be-
tween the viral peak during acute infection and the viral set point
established during chronic infection (Stafford et al., 2000). We
hypothesized that incorporating a canonical adaptive immune
response (De Boer and Perelson, 1998; Nowak and May, 2000)
would also be necessary to observe the reduced level of latently
infected cells documented during chronic infection.
A substantial body of literature suggests that the model as-
sumptions thatplat and r are constantmust be relaxed to account
for the adaptive immune response. In particular, the activation
levels of CD4+ T cells appear to increase during chronic infection
in vivo, as is measured by the expression levels of three activa-
tion markers (Li et al., 2005) and the increased turnover rates
of CD4+ T cells (Mohri et al., 1998). While the exact mechanism
is unknown, one potential driver of CD4+ T cell activation is the
body’s homeostatic response to the depletion of CD4+ T cells
during acute infection (Mohri et al., 1998). Another potential
mechanism is CD8+ T cells’ secreting activating cytokines
such as TNF-a (Murphy, 2011). Whatever the mechanism,
cellular activation factors sharply decrease plat and sharply acti-
vate HIV transcription (Calvanese et al., 2013; Chun et al., 1998;
Siliciano and Greene, 2011), for example, by accumulating tran-
scription factors (e.g., NF-kB) that activate the HIV LTR pro-
moter. Further, in the companion study (Razooky et al., 2015),
mathematical modeling shows that cellular activation levels
bias HIV circuit output (i.e., plat and r), even though latency is
hardwired into the circuit.Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc. 1007
AB
Figure 3. Incorporating the Immune Response Explains the Diver-
gent HIV-Latency Frequencies between Experimental Models and
Patients
(A) Extended model of systemic HIV infection, which includes CD8+ T cells (E)
that kill actively infected cells (or suppress viral replication) and activate
latently infected cells (Equations [S9] and [S10]).
(B) The latency probability (plat) and reactivation rate (r) change dramatically
around the time of the viremia peak due to the immune response (e.g., due to
bystander cytokine activation by immune cells, Equation [S10]). Inclusion of
immune cells into the model is capable of interpreting the low incidence of
latently infected cells in chronically infected patients.Since an adaptive immune response is associated with an in-
crease in CD4+ T cell activation levels (Li et al., 2005) that re-
duces plat and increases r (Calvanese et al., 2013; Chun et al.,
1998; Siliciano and Greene, 2011), we hypothesized that the
adaptive-immune response could be responsible for the
reduced plat levels in chronically infected patients (Figure 3A).
This hypothesis was quantitatively tested by allowing plat and r
to vary as functions of the effector CD8+ T cell concentration,
E[t] (Extended Experimental Procedures, Section C). Before
the initiation of the adaptive-immune response (i.e., before
chronic infection), the model naturally generates high latency
probabilities of 0.5 and low reactivation rates, as in the simpli-1008 Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc.fiedmodels above. However, after the viremia peak, cellular acti-
vation (Li et al., 2005) and cell death (Doitsh et al., 2010) become
substantial, increasing r(E[t]) to high levels and decreasing plat(E
[t]) to low levels (Figure 3B). As a result, the immunemodel mech-
anistically explains the divergent latency frequencies measured
between experimental models (cell culture and non-human pri-
mates) and chronically infected patients (Figure 3B).
Models Incorporating the Immune Response Fit
Available Patient Data while Retaining the Robust
Optimal Latency Prediction
While the immune-responsemodel interprets the low levels ofplat
measuredduring chronic infection, validation against all available
patient data is acritical test of themodel. Thus,we testedwhether
themodel could recapitulate extant patient data on: (1) viral loads
before ART (Fraser et al., 2007), (2) effector T cell concentrations
before ART (Turnbull et al., 2009), (3) latently infected cells before
ART (Chun et al., 1997b), and (4) latently infected cells after ART
(Finzi et al., 1999). Strikingly, the extended immune-response
model is able to fit these four data plateaus (Figure 4A), using
established parameter estimates (Table S2). In particular, the im-
mune-response model reproduces the depressed latent reser-
voir of 106 cells measured in chronically infected patients.
Further, themodel captures the1 log drop in the latent reservoir
under ART (Figure 4A), because ART leads to antigen depletion.
This causes the immune-cell population to contract and the reac-
tivation rate r(t) to decrease to its low background level. To be
sure that these fits were not artifacts due to model complexity,
we also tested simplified immune response models (Extended
Experimental Procedures, Section E). While these simplified
models fit the four steady-state plateaus, they cannot reproduce
the pre-steady-state kinetics measured in patients (Figure S3). In
contrast, the full immune model fits both steady-state and pre-
steady-state kinetics (Figure 4A, inset), including the viral decay
kinetics measured in patients who undergo ART (Markowitz
et al., 2003).
Critically, the level of the adaptive immune response does not
change the prediction of the simplified model (i.e., the model
without an immune response) that the initial latency probability
platð0Þ has a large optimum of 0.5 (Figures 4B and S3). As a
result, the prediction of the high optimal latency probability is
directly applicable to natural lentiviral hosts even if they exhibit
depressed immune responses. Further, as in the simplified
models lacking an immune response, the large poptlat value is pre-
served even when a large fraction of systemic infections are
mediated by non-latent cells (Extended Experimental Proce-
dures, Section E). The optimal latency prediction is also robust
to perturbations of epidemiological assumptions, such as the
monotonic dependence of lentiviral transmission on viral loads
(Extended Experimental Procedures, Section E). Overall, the
robustness of poptlat in the immune model matches the robustness
of poptlat in the simplified models.
Experimental Depletion of CD8+ T Cells in SIV-Infected
Macaques Will Increase the Latent Reservoir 3 Logs
More Than Viremia
The immune model argues that CD8+ T cells depress the latent
reservoir during chronic infection—either directly (e.g., through
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Figure 4. The Extended Immune-Response Model Fits the Available
In Vivo Data and Does Not Change the Optimal Latency Probability
for Resting Cells, poptlat (0)
(A) Dynamics of cell compartments during systemic infection calculated from
Equations [S9] and [S10]. Antiretroviral therapy (ART) initiated during steady-
state infectioncausesadeclineof the latent reservoir (L). Thesaturationof the fall
in the latent reservoir is due to the decline in immune cells (E) during ART. (Data
points across human patients) Virus load prior to ART (Fraser et al., 2007) (green
triangles); latent cellsprior toART (Chunet al., 1997b) andafter highlyactiveART
(Finzi et al., 1997) (cyan triangles); effector CD8 T cells (Turnbull et al., 2009) (red
triangles). For each data set (triangles), box-and-whisker plots show the upper
and lowerquartilesof thepatientdata. (Blowout)Virus loadafter theonsetofART
(Markowitz et al., 2003) (green triangles, error bars show SD).
(B) Normalized transmission rate ptransmission as a function of plat(0) calculated
from the dynamics in A and Equation [1]. Two cases are shown for comparison:
with immune cells (E, green triangles) and without immune cells (E =N = 0, blue
curve). Inclusion of immune cells into the model only weakly affects the pre-
diction of a large optimal latency probability for resting cells, poptlat (0) 0.5.
Model parameters in A and B are in Tables S1 and S2 (with R0
LT = 15 and
plat(0) = 0.5 in A). See also Figure S3.secreted cytokines) or indirectly (e.g., through activation of
downstream cell types that secrete factors). Thus, a direct test
of the model can be achieved by depleting CD8+ T cells with
anti-CD8 antibodies. CD8 depletion should increase the latency
probability (plat) toward its original high value of 0.5 and
concomitantly decrease the reactivation rate (r) toward its orig-
inal low value. In fact, the model quantitatively predicts the
outcome of this experiment. Whereas previous CD8 depletion
studies have already measured an1–3 log increase in the num-
ber of actively infected cells following CD8 depletion in SIV-in-
fected Rhesus macaques (Jin et al., 1999; Metzner et al., 2000;
Schmitz et al., 1999), the model predicts that the latent reservoir
will increase by 5 logs following CD8 depletion (Figure 5A).
Thus, the increase in the latent reservoir would be 3 logs
greater than the increase in actively infected cells and viremia(Figure 5B). A corollary prediction is that CD8 depletion during
early pre-peak infection (Matano et al., 1998), prior to a high-level
adaptive immune response, will only increase the latent reservoir
2- to 3-fold and will thus be harder to reliably measure (Fig-
ure S4). Notably, these experimental tests of the model require
viral outgrowth assays (Finzi et al., 1997) since directly
measuring proviral DNAwill only report on actively infected cells,
which outnumber latently infected cells by orders of magnitude.
A viral outgrowth assay post-CD8 depletion would provide quan-
titative verification of the model and would consequently test the
model’s output that latency is a viral bet-hedging strategy tuned
by natural selection.
Viral Strains Engineered to Have Higher Replicative
Fitness—via Reduced Latency—Will Exhibit Lower
Infectivity in Animal-Model Mucosal Inoculations
A more direct experimental test of the model would involve
mucosal challenge experiments using recombinant SIV strains
engineered to have substantially reduced latency probabilities.
Engineering strains with reduced latency efficiencies appears
possible since different HIV-1 clades are already known to
exhibit different latency frequencies. These clade-specific differ-
ences appear to be driven by cis elements within the HIV-1 LTR
(Jeeninga et al., 2008; van der Sluis et al., 2011). The model
directly predicts that the reduced-latency recombinants will
establish self-propagating systemic infections less frequently
than the wild-type strains maintaining high latency frequencies.
Further, these reduced latency strains could be quantitatively
tested for increased replicative fitnesses via competitive growth
assays with wild-type strains. If decreasing latency both
increased replicative fitness and decreased successful lentiviral
transmission, this would directly show that proviral latency pro-
vides a bet-hedging advantage that increases viral transmission
despite reducing steady-state viral loads.
Proviral Latency Contrastedwith AlternateMechanisms
of Initial Viral Survival
A natural question is whether alternatives to latently infected
CD4+ T cells exist that also increase the probability of initial viral
survival in the mucosa. One proposed non-latent route is den-
dritic cell migration from the mucosa to the target-cell rich
lymphoid tissue (Kahn and Walker, 1998; Wu and KewalRamani,
2006). More specifically, Langerhans dendritic cells present in
the mucosa can be infected by HIV and are prone to migration
to the lymphoid tissue, where they can support subsequent
dissemination of HIV by cis transfer (Peressin et al., 2014). Yet,
Langerhans cells’ dissemination of HIV may be partially blocked
by neutralizing antibodies (Su et al., 2012). Follicular dendritic
cells may provide another route of viral survival; however, these
cells do not migrate to the mucosa (Murphy, 2011). In contrast to
dendritic cells, proviral latent cells are neither impacted by
neutralizing antibodies (being quiescent) nor blocked by the
mucosal barrier, which has been proposed to be a viral bottle-
neck (Haaland et al., 2009). Latency can thus act as a type of
‘‘Trojan horse’’ for the virus. More fundamentally, even if alterna-
tive routes of initial viral survival exist, the results of this study
(i.e., poptlat >0) remain robust as long as latency seeds some frac-
tion of systemic infections (Figures 2E and S2J).Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc. 1009
B10–1
10–4
10–2
10–3
Pre- Post-
 
Ra
tio
 o
f V
ira
l R
N
A
/m
l
to
 
La
te
n
t C
el
ls
A
Target (T)
Virus (V)
Immune (E)
Latent (L)
100 105 115 120110 125
1010
1012
108
106
107
109
103
105
Days Post-transmission (t)
Ce
lls
 p
e
r 
B
od
y
CD8 Cell Depletion
Vi
re
m
ia
, 
R
N
A
 
Co
py
/m
l
105/106
107/1011
CD8 Cell
Depletion
Figure 5. Depletion of CD8+ T Cells in SIV-In-
fected Macaques Is Predicted to Increase
the Latent Reservoir Significantly More
Than Viremia
(A) Predicted dynamics in systemic infection for the
extended model (Equations [S9] and [S10]). Data
points and parameters are as in Figure 4, with the
upper and lower quartiles of the patient data (tri-
angles) shown in box-and-whisker plots.
(B) The ratio of virions to latently infected cells will
be inverted following CD8+ T cell depletion (post-
depletion corresponds to day 125 in A). The dra-
matic 2-log increase in viremia has been observed,
as shown by the data points at 1 week post-
depletion in Jin et al. (1999) and Schmitz et al.
(1999). The dashed horizontal line at 103 RNA/ml/
cell corresponds to a 1:1 ratio of latently and
actively infected cell counts. Blue bars correspond
to the parameters and compartment sizes in the
simulation example in A. Themaximal expected errors (vertical bars) are estimated from thewhisker box borders in A (the twomiddle quartiles). Since the dynamic
balance between actively infected cells and latently infected cells is modulated by plat and r, the depletion of immune cells affecting plat and r is predicted to
change this balance and disproportionately increase the latent reservoir.
See also Figures S4 and S5.Suppressing Latent Reactivation in the First Week of
Infection Could Substantially Reduce the Latent
Reservoir, Enhancing ‘‘Kick-and-Kill’’ Therapy
The model presents a potential therapeutic strategy that ex-
ploits the need for latently infected cells to reactivate to both
establish systemic infection and dramatically increase the
size of the latent reservoir (Figure S5). Thus, if the early reac-
tivation rate were reduced—for example, by suppressing an-
tigen-presenting cell (APC) migration (Peressin et al., 2014) or
HIV transcriptional reactivation (Weinberger et al., 2008)—
systemic infection would be rendered less likely and the
latent reservoir size would be substantially decreased (Fig-
ure S5). While a caveat of this proposed approach is detec-
tion and treatment within the first week of infection, similar
early treatments have been achieved; for a review, see
Haase (2011). Critically, a substantially smaller latent reser-
voir of 102 cells would require the reactivation of far fewer
latent cells by imperfect ‘‘shock-and-kill’’ strategies (Archin
et al., 2012; Deeks, 2012). As a result, suppression of reac-
tivation during the first week of infection followed by shock
and kill could substantially enhance the chances of HIV
eradication.
Implications for Alternate Antiviral Therapy Approaches
A further implication of the result that latency is a hardwired,
evolutionarily maintained trait is that it may be easier to control
HIV by increasing, rather than purging, the latent reservoir (Dar
et al., 2014; Weinberger and Weinberger, 2013; Weinberger
et al., 2008). Current shock-and-kill therapies are fighting natu-
ral selection in attempting to reactivate each of 105 latent
cells. In contrast, discovering a non-toxic compound that
switches 90%–95% of actively infected cells to latency would
drive HIV’s basic reproductive ratio (R0) below 1, making HIV
infection unsustainable. While still a hypothetical avenue,
enhancing viral latency may provide a viable alternative if
shock-and-kill strategies fail to achieve their goal of complete
eradication.1010 Cell 160, 1002–1012, February 26, 2015 ª2015 Elsevier Inc.EXPERIMENTAL PROCEDURES
A Simplified Two-Compartment Model to Quantify the Net Impact of
Latency on Lentiviral Transmission
All models described in the main text are variations of the well-parameter-
ized basic model of viral dynamics (Nowak and May, 2000) expanded to
include latent infections (Rong and Perelson, 2009a, 2009b; Sedaghat
et al., 2007, 2008). Absent an immune response, the deterministic
form of the models is captured by the following ordinary differential
equations:
Uninfected 0target0 cells
dT
dt
= b|{z}
replenishment
 dTT|ﬄ{zﬄ}
natural death
 kVT|ﬄ{zﬄ}
infection
Actively infected cells
dI
dt
= ð1 platÞkVT|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
active infection
 dII|{z}
death
+ rL|{z}
reactivation
Latently infected cells
dL
dt
= platkVT|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
latent infection
 dLL|{z}
death
 rL|{z}
reactivation
Virus
dV
dt
= ndII|ﬄ{zﬄ}
production
 cV|{z}
clearance
[6]
In the model above, uninfected ‘‘target’’ cells (T) are produced at rate b,
decay at rate dT, and can be infected by virus particles (V) at rate k. Upon viral
infection, target cells become either latently infected cells (L) with probability
plat or become actively infected (virus-producing) cells (I) with probability 1 
plat. Latently infected cells reactivate into actively infected cells at rate r or
die at the (slow) rate dL. Actively infected cells produce ‘‘burst sizes’’ of n vi-
rions as they die at rate dI. Virions decay at the relatively fast rate c. All param-
eter values are given in Table S1; Table S2 contains parameters for the model
extended to include an adaptive immune response (Extended Experimental
Procedures, Section C).
Critically, the infection models can be simplified by re-parameterizing the
equations in termsof thebasic reproductive ratio:R0=bkn/cdT. This ‘‘non-dimen-
sionalization’’ enables us to capture the disparate dynamics between mucosal
infection (Figure 2A) and systemic infection (Figure 2B) by simulating the same
model for both infection stages and only varying a single parameter, R0. Further,
R0
muc is experimentally bounded to be < < 1 from the viral dynamics during initial
infection (Miller et al., 2005), andR0
LT is similarlymeasured to be10 during sys-
temic infection (Nowak and May, 2000). As a result, no assumptions about un-
known parameter values are needed to obtain the optimal latency probability
ðpoptlat Þ. More directly, Equation [5] shows that ðpoptlat Þ only depends on R0LT
(for detailed derivations and tests of the models, see Extended Experimental
Procedures).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2015.02.017.
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